Zentalis Pharmaceuticals (ZNTL) Operating Leases (2020 - 2026)

Zentalis Pharmaceuticals has reported Operating Leases for 7 years, with the latest figure at $34.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 10.35% year-over-year to $34.6 million; the trailing twelve-month figure through Mar 2026 stood at $34.6 million (down 10.35% YoY), and the FY2025 full-year result was $35.7 million, down 9.79% from the prior year.
• Operating Leases for Q1 2026 stood at $34.6 million, down from $35.7 million in the prior quarter.
• The five-year high for Operating Leases was $46.4 million in Q2 2023, with the low at $34.6 million in Q1 2026.
• Average Operating Leases over 5 years is $41.1 million, with a median of $40.9 million recorded in 2024.
• Year-over-year, Operating Leases climbed 1.59% in 2022 and decreased 14.78% in 2025.
• Tracing ZNTL's Operating Leases over 5 years: stood at $45.2 million in 2022, then retreated by 4.46% to $43.2 million in 2023, then slipped by 8.28% to $39.6 million in 2024, then retreated by 9.79% to $35.7 million in 2025, then slipped by 2.95% to $34.6 million in 2026.
• The last three Operating Leases figures came in at $34.6 million (Q1 2026), $35.7 million (Q4 2025), and $36.7 million (Q3 2025), per Business Quant data.

Peer Comparison